STAT Plus: Drug industry conferences are going virtual. Here’s how not to present data on Zoom
The coronavirus pandemic has upended the way the drug industry presents its data. In recent…
Category: STAT Plus
STAT Plus: With new data, experimental drug offers hope for new approach to treating schizophrenia
It’s been decades since the last meaningful advance in treating schizophrenia appeared. A new medicine…
STAT Plus: Pharmalittle: More than one coronavirus vaccine may be needed; Utah bill would protect docs prescribing meds for Covid-19
Hello, everyone, and how are you today? We are coping, thank you, despite the ongoing…
STAT Plus: Pharmacy chains gain a ‘solid’ victory in opioid litigation, but aren’t off the hook yet
As jockeying in the opioid litigation continues, a U.S. appeals court ruled several large pharmacy…
STAT Plus: Within months of birth, some pathogens are detectable in infants’ guts, new research shows
Bacteria have long been the star of microbiome research. But the human gut is not…
STAT Plus: This cancer company is biotech’s most volatile non-Covid-19 stock
In 2020, billions of dollars have been created and erased by speculation over which companies…
STAT Plus: Pharmalittle: Docs ask states for lethal injection drugs to combat Covid-19; Raw material costs for hydroxycholorquine slow production
Good morning, everyone, and how are you today? We are doing all right, under the…
.jpg)
STAT Plus: Startup TScan signs $30m deal with Novartis
TScan Therapeutics on Wednesday announced a $30 million deal with Swiss pharma giant Novartis (NVS)…
STAT Plus: Novo Nordisk becomes latest insulin maker seeking to foster goodwill amid Covid-19
Yet another large insulin maker is trying to soften the financial hit many people are…
STAT Plus: Pharmacy reimbursement often lags for generics undergoing price hikes, jeopardizing patient access
Of more than 4,300 instances in which pharmacies saw generic drug prices rise by 50%…
STAT Plus: Athersys pivots a stem cell therapy to Covid-19, but prior data offer little confidence
Athersys is confident its experimental stem cell therapy has the potential to help patients with the…
STAT Plus: State legislatures are lapping the federal government on drug pricing — even amid the coronavirus
A version of this article first ran in D.C. Diagnosis, STAT’s weekly newsletter about the…
STAT Plus: Vaccine development becomes reality TV. Can it make viewers rethink pharma?
The pharmaceutical industry’s response to the novel coronavirus may not rescue its ailing reputation. But…
STAT Plus: Pharmalittle: India to ramp up ingredients production; CIA warns employees about taking hydroxycholoroquine
Rise and shine, everyone, another challenging day is on the way. We can tell because…
STAT Plus: Blackstone Group invests up to $2 billion in Alnylam, a big bet on the Cambridge biotech
The private equity firm Blackstone Group is investing up to $2 billion in Alnylam Pharmaceuticals,…
STAT Plus: Zai Lab targets blood cancers in deal with Regeneron
Shanghai’s Zai Lab (ZLAB) is adding a blood cancer drug to its pipeline through a…
STAT Plus: Biotech in the time of coronavirus: The return of mergers, acquisitions, and deals
Seeing the Easter Bunny wear a mask was weird. Greetings and welcome to another semi-regular…
STAT Plus: Pharmalittle: Gilead Covid-19 drug shows early promise; AstraZeneca halts trial due to ‘overwhelming’ benefit
Good morning, everyone, and welcome to another working week. We hope the weekend respite —…
STAT Plus: Study of AstraZeneca’s top-selling cancer drug stopped early for ‘overwhelming’ benefit
AstraZeneca halted a study of its lung cancer treatment Tagrisso after observing what the company…
STAT Plus: Insurers, drug makers, and patient advocates blast two Trump proposals to drive down drug prices
WASHINGTON — The Trump administration has proposed modest steps this year to promote biosimilar and…
STAT Plus: Pharmalittle: Poison control sees more cases after Trump touts malaria drug; Indian companies to double hydroxychloroquine output
And so, another working week will soon come to a close. Not a moment too…
STAT Plus: How will the pandemic shape biotech in the months ahead? An industry analyst weighs in
The biopharma industry is racing to respond to the novel coronavirus pandemic. But the industry…
STAT Plus: Video Chat: How the coronavirus pandemic is testing health tech
Editor’s note: The live stream will be embedded below at 1 p.m EST. The health…
STAT Plus: Pharmalittle: More clinical trials derailed by Covid-19; Pfizer jumpstarts tests on a drug to fight the pandemic
Rise and shine, everyone, another challenging day is on the way. And while it will…
STAT Plus: Biotech venture capital had a record-breaking quarter, but isn’t out of the woods yet
A version of this story also appeared in STAT’s daily biotech newsletter, The Readout. Subscribe…
STAT Plus: Opioid-overdose prescriptions may go unfilled due to the cost
Although naloxone is widely regarded as an effective antidote for reversing opioid overdoses, a new…
STAT Plus: Roche partners with Arrakis Therapeutics to develop drugs that target RNA
Last year, Arrakis Therapeutics announced early but important progress toward a drug-development goal long thought…
STAT Plus: A rare investment mechanism is helping to fund some health tech companies’ coronavirus projects
Extraordinary times call for extraordinary financing instruments, according to one California venture capital firm. A…
STAT Plus: Pharmalittle: India to allow limited exports of malaria drug; some Trump allies profit if hydroxychloroquine is approved
Good morning, everyone, and how are you today? As the saying goes, stay on the…
STAT Plus: Biotech in the time of coronavirus: Pondering the future of ‘JPM Week’
I logged into a Zoom meeting wearing a fuzzy robe. Greetings and welcome to another…
STAT Plus: Alnylam and Dicerna, onetime rivals, announce a ceasefire
Rival biotechs Alnylam and Dicerna are announcing a ceasefire. The two companies, which are both…
STAT Plus: Pharmalittle: States try to prevent hoarding of drug used for Covid-19; is BARDA ready for the coronavirus?
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT Plus: Immunomedics halts late-stage clinical trial, confirming drug benefit for aggressive type of breast cancer
Immunomedics is stopping a Phase 3 clinical trial due to “compelling evidence of efficacy” demonstrated…
STAT Plus: Boston Scientific cutting hours and pay as revenue drops
Boston Scientific said Thursday that it’s cutting wages for many of its roughly 36,000 global…
STAT Plus: Pharmalittle: Sanofi poised to supply millions of doses of malaria drug; Roche unit apologizes for ‘Wuhan’ virus label
And so, another working week will soon draw to a close. Not a moment too…
STAT Plus: ‘Science is very much a part of culture’: Siddhartha Mukherjee dives into the history of genetics in a new Ken Burns film
One of the world’s most well-known oncologists and one of the world’s most well-known documentary…
STAT Plus: Large employers could have saved money if more biosimilars had been prescribed
If some of the largest U.S. employers had used biosimilar versions of a pair of…
STAT Plus: The latest failure in Alzheimer’s casts doubt on Biogen’s ostensible success
The prevailing theory of how to treat Alzheimer’s disease endured its 1,001st cut on Thursday,…
STAT Plus: Pharmalittle: Novartis scraps generic sale to Aurobindo; another small study suggests old malaria drug works
Rise and shine, everyone, another busy day is on the way. How could it be…
STAT Plus: Big biotech venture funds raise billions despite coronavirus fears
The economy is grinding to a near-halt because of Covid-19. In the biotechnology sector, which…
STAT Plus: Two companies bet on ‘chemogenetics’ to sidestep challenges with neurological drug development
For years, pharmaceutical companies have cut back on drug development that targeted neurological conditions. After…
STAT Plus: CDC credits a sharp decline in C. diff infections to checklists and better antibiotic stewardship
The rate of Americans contracting potentially fatal Clostridium difficile bacterial infections in hospitals fell between…
STAT Plus: The FDA warns Pfizer over yet another former Hospira manufacturing plant
Amid ongoing concerns over the pharmaceutical supply chain, the Food and Drug Administration has issued…
STAT Plus: FDA asks manufacturers to recall heartburn drugs over traces of a possible carcinogen
After months of deliberation, the Food and Drug Administration has asked all manufacturers of a…
STAT Plus: Pharmalittle: U.S. asks India to list restrictions on pharma ingredients; Giuliani wants FDA to fast-track a drug for Covid-19
Good morning, everyone, and welcome to the middle of the week. Given that so many…
STAT Plus: The biotech scorecard for the second quarter: 18 stock-moving events to watch
Here is STAT’s Biotech Scorecard, our regular ledger of stock-moving biotech events, for the second…
STAT Plus: Pharmalittle: A TB vaccine is tested against the coronavirus; FDA doesn’t punish Novartis over data integrity scandal
Hello, everyone, and how are you coping this morning? We are doing just fine, thank…
STAT Plus: FDA closes review of Novartis data integrity scandal without punishing the drug maker
An embarrassing scandal that Novartis (NVS) endured over data integrity has quietly come to a…
STAT Plus: ‘It’s the disparity in who gets affected’: A sickle cell doctor tracks dollars and drug development
Sickle cell disease and cystic fibrosis are both rare, genetic diseases. While there are three…
STAT Plus: Pharmalittle: Drug pricing legislation is on the back burner; FDA issues emergency use for old malaria drugs
Good morning, everyone, and welcome to another working week, although it may not quite seem…